Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40040 | 0.91 | — | — | |
| SCHEMBL18351061 | 0.91 | POLB (0.38) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL9286352 | 0.89 | CXCR4 (0.40) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL18770806 | 0.89 | SMN1; SMN2 (0.37) | CXCR4SIGMAR1CHRM5CHRM3POLB | |
| SCHEMBL14037795 | 0.89 | POLB (0.37) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL11669571 | 0.82 | CXCR4 (0.54) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL1999568 | 0.79 | CXCR4 (0.57) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL13671432 | 0.79 | CXCR4 (0.34) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL64922 | 0.78 | CXCR4 (0.50) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL8757759 | 0.78 | CXCR4 (0.50) | CXCR4MEN1CHRM2CHRM1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| EP-2991982-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-03-09 | — | — | EP | disclosed |
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2842956-A1 | PARP inhibitor compounds, compositions and methods of use | Eisai Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8894989-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2014-11-25 | — | — | US | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8236802-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2209375-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Eisai Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MGI GP, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009046205-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI RESEARCH INSTITUTE (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | CXCR4 3463/4885MEN1 1486/4885CHRM2 4879/4885 |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | CXCR4 3355/4885MEN1 3934/4885CHRM2 3441/4885 |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | CXCR4 3463/4885MEN1 1486/4885CHRM2 4879/4885 |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | CXCR4 3355/4885MEN1 3934/4885CHRM2 3441/4885 |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | CXCR4 3569/4885MEN1 1470/4885CHRM2 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.